These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28326274)

  • 1. The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer.
    Azijli K; Gotink KJ; Verheul HM
    J Kidney Cancer VHL; 2015; 2(4):195-203. PubMed ID: 28326274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.
    Sweeney PL; Suri Y; Basu A; Koshkin VS; Desai A
    Cancer Drug Resist; 2023; 6(4):858-873. PubMed ID: 38239394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
    Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
    Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
    Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
    Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance‑related sunitinib sequestration in autophagolysosomes of endothelial cells.
    Wu S; Huang L; Shen R; Bernard-Cacciarella M; Zhou P; Hu C; Di Benedetto M; Janin A; Bousquet G; Li H; He Z; Lu H
    Int J Oncol; 2020 Jan; 56(1):113-122. PubMed ID: 31789391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
    Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
    J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
    Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
    EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.
    Elgendy M; Fusco JP; Segura V; Lozano MD; Minucci S; Echeveste JI; Gurpide A; Andueza M; Melero I; Sanmamed MF; Ruiz MR; Calvo A; Pascual JI; Velis JM; Miñana B; Valle RD; Pio R; Agorreta J; Abengozar M; Colecchia M; Brich S; Renne SL; Guruceaga E; Patiño-García A; Perez-Gracia JL
    Int J Cancer; 2019 Oct; 145(7):1991-2001. PubMed ID: 30848481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
    Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
    Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib treatment for multifocal renal cell carcinoma (RCC) and pancreatic neuroendocrine tumor (NET) in patient with Von Hippel-Lindau disease. Case Report.
    Babinska A; Studniarek M; Świątkowska-Stodulska R; Sworczak K
    Neuro Endocrinol Lett; 2015 Dec; 36(6):517-20. PubMed ID: 26812297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
    Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM
    FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
    Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
    Giuliano S; Cormerais Y; Dufies M; Grépin R; Colosetti P; Belaid A; Parola J; Martin A; Lacas-Gervais S; Mazure NM; Benhida R; Auberger P; Mograbi B; Pagès G
    Autophagy; 2015; 11(10):1891-904. PubMed ID: 26312386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
    Gobe GC; Ng KL; Small DM; Vesey DA; Johnson DW; Samaratunga H; Oliver K; Wood S; Barclay JL; Rajandram R; Li L; Morais C
    Biochem Biophys Res Commun; 2016 Apr; 473(1):47-53. PubMed ID: 26995091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
    Tran TA; Leong HS; Pavia-Jimenez A; Fedyshyn S; Yang J; Kucejova B; Sivanand S; Spence P; Xie XJ; Peña-Llopis S; Power N; Brugarolas J
    Mol Cell Biol; 2016 Jul; 36(13):1836-55. PubMed ID: 27141054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.